Cytokinetics price target lowered to $117 from $119 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm's price target on Cytokinetics to $117 from $119 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June